Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
AB Science announces recruitment of first patient in phase 3 study of masitinib in progressive multiple sclerosis
Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process)
Genetic analysis of aquaporin-4 in neuromyelitis optica.
[Neurophysiology in Guillain-Barré syndrome].
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
Interferon-ß-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
12-oxo-phytodienoic acid, a plant-derived oxylipin, attenuates lipopolysaccharide-induced inflammation in microglia.
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Novantrone
Chronic mild stress eliminates the neuroprotective effect of Copaxone after CNS injury.
Drugs@FDA
Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD.
The role of global and regional gray matter volume decrease in multiple sclerosis.

Pages